With the skinny trend resurfacing, the issue is that what a person watches and engages with through likes, saves, replays, etc., they get served more of
Report Scope
Based on the current stage of clinical development and estimated trial completion dates registered on ClinicalTrials.gov, a realistic earliest possible timeline might be considered as follows: 20252026: Completion of key phase 3 TRIUMPH trial data 20262027: Potential regulatory submission to the MHRA (and FDA/EMA in parallel) 20272028: Possible MHRA marketing authorisation, subject to satisfactory review 2028 onwards: NICE technology appraisal and potential NHS commissioning decision These timelines are speculative and depend on multiple variables, including trial outcomes, the completeness of the regulatory submission, MHRA review timelines, and NICE deliberations
Novo Nordisk Files for FDA Approval of CagriSema, The First Once-Weekly Combination of GLP-1 and Amylin Analogues for Weight Management
170 This also applies to DR: a thorough investigation of the life-prolonging effects of DR in mice shows that weight gain in the ad libitum fed control group is the most important covariate explaining most of the variation in the response of different strains to DR